TTPNetwork’s response to the NICE Decision on the use of Caplacizumab in the treatment of TTP

Update 16th December 2020 The Final Guidance has now been published on the NICE website: www.nice.org.uk/guidance/TA667   TTPNetwork’s response to the NICE Decision on the use of Caplacizumab in the treatment of TTP Nice have today published the following decision: Caplacizumab with plasma exchange and immunosuppression is recommended, within its marketing authorisation, as an option for…